Frailty after kidney transplantation is a harbinger for death and other major adverse outcomes in hospitalized patients. The hospital frailty risk score (HFRS) predicts graft failure, severe infection ...
Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results